My ePortfolio Register   

'Killer peptide' that helps eliminate resistant cancer cells discovered

A new study by University of Kentucky Markey Cancer Center researchers shows that when therapy-sensitive cancer cells die, they release a "killer peptide" that can eliminate therapy-resistant cells.

Tumour relapse is a common problem following cancer treatment, because primary tumour cells often contain therapy-resistance cancer cells that continue to proliferate after the therapy-sensitive cells have been eliminated.

In the study, published in Cancer Research, Markey scientists identified a Par-4 amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced cleavage of the tumour suppressor Par-4 protein.

PAF caused death in cancer cells resistant to therapy and inhibited metastatic tumour growth in mice.

Additionally, the PAF entered only cancer cells, not normal cells, keeping healthy tissue intact.

The findings indicate that this naturally generated PAF could potentially be harnessed to target neighbouring or distant cancer cells to overcome metastasis and therapy resistance in tumours.

"This new information could positively impact how physicians plan their treatments, so as to use the sensitive cells in the tumour to release this peptide to help eliminate the resistant cells," said Vivek Rangnekar, principal investigator and Alfred Cohen Chair in Oncology Research with the UK College of Medicine's Department of Radiation Medicine.

"We are developing PAF against therapy-resistant tumour metastasis for which no other treatment options are available."

Markey researchers Nikhil Hebbar and Ravshan Burikhanov from Rangnekar's team were the first two authors on the study, which also involved a partnership with Dr Kojo Elenitoba-Johnson at the University of Pennsylvania.

Rangnekar's team first announced the generation of the cancer-resistant Par-4 mouse back in 2007.

Since then, his team's work has spawned numerous research projects focusing on preventing and treating many types of cancer, including Markey oncologist Dr Peng Wang's clinical trial using the anti-malarial drug hydroxychloroquine to induce Par-4 secretion.

Source: University of Kentucky

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence